دورية أكاديمية
أعرض في EDS

A SARS-CoV-2 protein interaction map reveals targets for drug repurposing.

التفاصيل البيبلوغرافية
العنوان: A SARS-CoV-2 protein interaction map reveals targets for drug repurposing.
المؤلفون: Gordon DE; QBI COVID-19 Research Group (QCRG), San Francisco, CA, USA.; Quantitative Biosciences Institute (QBI), University of California San Francisco, San Francisco, CA, USA.; J. David Gladstone Institutes, San Francisco, CA, USA.; Department of Cellular and Molecular Pharmacology, University of California San Francisco, San Francisco, CA, USA., Jang GM; QBI COVID-19 Research Group (QCRG), San Francisco, CA, USA.; Quantitative Biosciences Institute (QBI), University of California San Francisco, San Francisco, CA, USA.; J. David Gladstone Institutes, San Francisco, CA, USA.; Department of Cellular and Molecular Pharmacology, University of California San Francisco, San Francisco, CA, USA., Bouhaddou M; QBI COVID-19 Research Group (QCRG), San Francisco, CA, USA.; Quantitative Biosciences Institute (QBI), University of California San Francisco, San Francisco, CA, USA.; J. David Gladstone Institutes, San Francisco, CA, USA.; Department of Cellular and Molecular Pharmacology, University of California San Francisco, San Francisco, CA, USA., Xu J; QBI COVID-19 Research Group (QCRG), San Francisco, CA, USA.; Quantitative Biosciences Institute (QBI), University of California San Francisco, San Francisco, CA, USA.; J. David Gladstone Institutes, San Francisco, CA, USA.; Department of Cellular and Molecular Pharmacology, University of California San Francisco, San Francisco, CA, USA., Obernier K; QBI COVID-19 Research Group (QCRG), San Francisco, CA, USA.; Quantitative Biosciences Institute (QBI), University of California San Francisco, San Francisco, CA, USA.; J. David Gladstone Institutes, San Francisco, CA, USA.; Department of Cellular and Molecular Pharmacology, University of California San Francisco, San Francisco, CA, USA., White KM; Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.; Global Health and Emerging Pathogens Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA., O'Meara MJ; Department of Computational Medicine and Bioinformatics, University of Michigan, Ann Arbor, MI, USA., Rezelj VV; Viral Populations and Pathogenesis Unit, CNRS UMR 3569, Institut Pasteur, Paris, France., Guo JZ; QBI COVID-19 Research Group (QCRG), San Francisco, CA, USA.; Quantitative Biosciences Institute (QBI), University of California San Francisco, San Francisco, CA, USA.; J. David Gladstone Institutes, San Francisco, CA, USA.; Department of Cellular and Molecular Pharmacology, University of California San Francisco, San Francisco, CA, USA., Swaney DL; QBI COVID-19 Research Group (QCRG), San Francisco, CA, USA.; Quantitative Biosciences Institute (QBI), University of California San Francisco, San Francisco, CA, USA.; J. David Gladstone Institutes, San Francisco, CA, USA.; Department of Cellular and Molecular Pharmacology, University of California San Francisco, San Francisco, CA, USA., Tummino TA; QBI COVID-19 Research Group (QCRG), San Francisco, CA, USA.; Quantitative Biosciences Institute (QBI), University of California San Francisco, San Francisco, CA, USA.; Department of Pharmaceutical Chemistry, University of California San Francisco, San Francisco, CA, USA., Hüttenhain R; QBI COVID-19 Research Group (QCRG), San Francisco, CA, USA.; Quantitative Biosciences Institute (QBI), University of California San Francisco, San Francisco, CA, USA.; J. David Gladstone Institutes, San Francisco, CA, USA.; Department of Cellular and Molecular Pharmacology, University of California San Francisco, San Francisco, CA, USA., Kaake RM; QBI COVID-19 Research Group (QCRG), San Francisco, CA, USA.; Quantitative Biosciences Institute (QBI), University of California San Francisco, San Francisco, CA, USA.; J. David Gladstone Institutes, San Francisco, CA, USA.; Department of Cellular and Molecular Pharmacology, University of California San Francisco, San Francisco, CA, USA., Richards AL; QBI COVID-19 Research Group (QCRG), San Francisco, CA, USA.; Quantitative Biosciences Institute (QBI), University of California San Francisco, San Francisco, CA, USA.; J. David Gladstone Institutes, San Francisco, CA, USA.; Department of Cellular and Molecular Pharmacology, University of California San Francisco, San Francisco, CA, USA., Tutuncuoglu B; QBI COVID-19 Research Group (QCRG), San Francisco, CA, USA.; Quantitative Biosciences Institute (QBI), University of California San Francisco, San Francisco, CA, USA.; J. David Gladstone Institutes, San Francisco, CA, USA.; Department of Cellular and Molecular Pharmacology, University of California San Francisco, San Francisco, CA, USA., Foussard H; QBI COVID-19 Research Group (QCRG), San Francisco, CA, USA.; Quantitative Biosciences Institute (QBI), University of California San Francisco, San Francisco, CA, USA.; J. David Gladstone Institutes, San Francisco, CA, USA.; Department of Cellular and Molecular Pharmacology, University of California San Francisco, San Francisco, CA, USA., Batra J; QBI COVID-19 Research Group (QCRG), San Francisco, CA, USA.; Quantitative Biosciences Institute (QBI), University of California San Francisco, San Francisco, CA, USA.; J. David Gladstone Institutes, San Francisco, CA, USA.; Department of Cellular and Molecular Pharmacology, University of California San Francisco, San Francisco, CA, USA., Haas K; QBI COVID-19 Research Group (QCRG), San Francisco, CA, USA.; Quantitative Biosciences Institute (QBI), University of California San Francisco, San Francisco, CA, USA.; J. David Gladstone Institutes, San Francisco, CA, USA.; Department of Cellular and Molecular Pharmacology, University of California San Francisco, San Francisco, CA, USA., Modak M; QBI COVID-19 Research Group (QCRG), San Francisco, CA, USA.; Quantitative Biosciences Institute (QBI), University of California San Francisco, San Francisco, CA, USA.; J. David Gladstone Institutes, San Francisco, CA, USA.; Department of Cellular and Molecular Pharmacology, University of California San Francisco, San Francisco, CA, USA., Kim M; QBI COVID-19 Research Group (QCRG), San Francisco, CA, USA.; Quantitative Biosciences Institute (QBI), University of California San Francisco, San Francisco, CA, USA.; J. David Gladstone Institutes, San Francisco, CA, USA.; Department of Cellular and Molecular Pharmacology, University of California San Francisco, San Francisco, CA, USA., Haas P; QBI COVID-19 Research Group (QCRG), San Francisco, CA, USA.; Quantitative Biosciences Institute (QBI), University of California San Francisco, San Francisco, CA, USA.; J. David Gladstone Institutes, San Francisco, CA, USA.; Department of Cellular and Molecular Pharmacology, University of California San Francisco, San Francisco, CA, USA., Polacco BJ; QBI COVID-19 Research Group (QCRG), San Francisco, CA, USA.; Quantitative Biosciences Institute (QBI), University of California San Francisco, San Francisco, CA, USA.; J. David Gladstone Institutes, San Francisco, CA, USA.; Department of Cellular and Molecular Pharmacology, University of California San Francisco, San Francisco, CA, USA., Braberg H; QBI COVID-19 Research Group (QCRG), San Francisco, CA, USA.; Quantitative Biosciences Institute (QBI), University of California San Francisco, San Francisco, CA, USA.; J. David Gladstone Institutes, San Francisco, CA, USA.; Department of Cellular and Molecular Pharmacology, University of California San Francisco, San Francisco, CA, USA., Fabius JM; QBI COVID-19 Research Group (QCRG), San Francisco, CA, USA.; Quantitative Biosciences Institute (QBI), University of California San Francisco, San Francisco, CA, USA.; J. David Gladstone Institutes, San Francisco, CA, USA.; Department of Cellular and Molecular Pharmacology, University of California San Francisco, San Francisco, CA, USA., Eckhardt M; QBI COVID-19 Research Group (QCRG), San Francisco, CA, USA.; Quantitative Biosciences Institute (QBI), University of California San Francisco, San Francisco, CA, USA.; J. David Gladstone Institutes, San Francisco, CA, USA.; Department of Cellular and Molecular Pharmacology, University of California San Francisco, San Francisco, CA, USA., Soucheray M; QBI COVID-19 Research Group (QCRG), San Francisco, CA, USA.; Quantitative Biosciences Institute (QBI), University of California San Francisco, San Francisco, CA, USA.; J. David Gladstone Institutes, San Francisco, CA, USA.; Department of Cellular and Molecular Pharmacology, University of California San Francisco, San Francisco, CA, USA., Bennett MJ; QBI COVID-19 Research Group (QCRG), San Francisco, CA, USA.; Quantitative Biosciences Institute (QBI), University of California San Francisco, San Francisco, CA, USA.; J. David Gladstone Institutes, San Francisco, CA, USA.; Department of Cellular and Molecular Pharmacology, University of California San Francisco, San Francisco, CA, USA., Cakir M; QBI COVID-19 Research Group (QCRG), San Francisco, CA, USA.; Quantitative Biosciences Institute (QBI), University of California San Francisco, San Francisco, CA, USA.; J. David Gladstone Institutes, San Francisco, CA, USA.; Department of Cellular and Molecular Pharmacology, University of California San Francisco, San Francisco, CA, USA., McGregor MJ; QBI COVID-19 Research Group (QCRG), San Francisco, CA, USA.; Quantitative Biosciences Institute (QBI), University of California San Francisco, San Francisco, CA, USA.; J. David Gladstone Institutes, San Francisco, CA, USA.; Department of Cellular and Molecular Pharmacology, University of California San Francisco, San Francisco, CA, USA., Li Q; QBI COVID-19 Research Group (QCRG), San Francisco, CA, USA.; Quantitative Biosciences Institute (QBI), University of California San Francisco, San Francisco, CA, USA.; J. David Gladstone Institutes, San Francisco, CA, USA.; Department of Cellular and Molecular Pharmacology, University of California San Francisco, San Francisco, CA, USA., Meyer B; Viral Populations and Pathogenesis Unit, CNRS UMR 3569, Institut Pasteur, Paris, France., Roesch F; Viral Populations and Pathogenesis Unit, CNRS UMR 3569, Institut Pasteur, Paris, France., Vallet T; Viral Populations and Pathogenesis Unit, CNRS UMR 3569, Institut Pasteur, Paris, France., Mac Kain A; Viral Populations and Pathogenesis Unit, CNRS UMR 3569, Institut Pasteur, Paris, France., Miorin L; Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.; Global Health and Emerging Pathogens Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA., Moreno E; Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.; Global Health and Emerging Pathogens Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA., Naing ZZC; QBI COVID-19 Research Group (QCRG), San Francisco, CA, USA.; Quantitative Biosciences Institute (QBI), University of California San Francisco, San Francisco, CA, USA.; J. David Gladstone Institutes, San Francisco, CA, USA.; Department of Cellular and Molecular Pharmacology, University of California San Francisco, San Francisco, CA, USA., Zhou Y; QBI COVID-19 Research Group (QCRG), San Francisco, CA, USA.; Quantitative Biosciences Institute (QBI), University of California San Francisco, San Francisco, CA, USA.; J. David Gladstone Institutes, San Francisco, CA, USA.; Department of Cellular and Molecular Pharmacology, University of California San Francisco, San Francisco, CA, USA., Peng S; QBI COVID-19 Research Group (QCRG), San Francisco, CA, USA.; Quantitative Biosciences Institute (QBI), University of California San Francisco, San Francisco, CA, USA.; Department of Pharmaceutical Chemistry, University of California San Francisco, San Francisco, CA, USA., Shi Y; QBI COVID-19 Research Group (QCRG), San Francisco, CA, USA.; Quantitative Biosciences Institute (QBI), University of California San Francisco, San Francisco, CA, USA.; Department of Cellular and Molecular Pharmacology, University of California San Francisco, San Francisco, CA, USA.; Howard Hughes Medical Institute, University of California San Francisco, San Francisco, CA, USA., Zhang Z; QBI COVID-19 Research Group (QCRG), San Francisco, CA, USA.; Quantitative Biosciences Institute (QBI), University of California San Francisco, San Francisco, CA, USA.; Department of Cellular and Molecular Pharmacology, University of California San Francisco, San Francisco, CA, USA.; Howard Hughes Medical Institute, University of California San Francisco, San Francisco, CA, USA., Shen W; QBI COVID-19 Research Group (QCRG), San Francisco, CA, USA.; Quantitative Biosciences Institute (QBI), University of California San Francisco, San Francisco, CA, USA.; Department of Cellular and Molecular Pharmacology, University of California San Francisco, San Francisco, CA, USA.; Howard Hughes Medical Institute, University of California San Francisco, San Francisco, CA, USA., Kirby IT; QBI COVID-19 Research Group (QCRG), San Francisco, CA, USA.; Quantitative Biosciences Institute (QBI), University of California San Francisco, San Francisco, CA, USA.; Department of Cellular and Molecular Pharmacology, University of California San Francisco, San Francisco, CA, USA.; Howard Hughes Medical Institute, University of California San Francisco, San Francisco, CA, USA., Melnyk JE; QBI COVID-19 Research Group (QCRG), San Francisco, CA, USA.; Quantitative Biosciences Institute (QBI), University of California San Francisco, San Francisco, CA, USA.; Department of Cellular and Molecular Pharmacology, University of California San Francisco, San Francisco, CA, USA.; Howard Hughes Medical Institute, University of California San Francisco, San Francisco, CA, USA., Chorba JS; QBI COVID-19 Research Group (QCRG), San Francisco, CA, USA.; Quantitative Biosciences Institute (QBI), University of California San Francisco, San Francisco, CA, USA.; Department of Cellular and Molecular Pharmacology, University of California San Francisco, San Francisco, CA, USA.; Howard Hughes Medical Institute, University of California San Francisco, San Francisco, CA, USA., Lou K; QBI COVID-19 Research Group (QCRG), San Francisco, CA, USA.; Quantitative Biosciences Institute (QBI), University of California San Francisco, San Francisco, CA, USA.; Department of Cellular and Molecular Pharmacology, University of California San Francisco, San Francisco, CA, USA.; Howard Hughes Medical Institute, University of California San Francisco, San Francisco, CA, USA., Dai SA; QBI COVID-19 Research Group (QCRG), San Francisco, CA, USA.; Quantitative Biosciences Institute (QBI), University of California San Francisco, San Francisco, CA, USA.; Department of Cellular and Molecular Pharmacology, University of California San Francisco, San Francisco, CA, USA.; Howard Hughes Medical Institute, University of California San Francisco, San Francisco, CA, USA., Barrio-Hernandez I; European Molecular Biology Laboratory (EMBL), European Bioinformatics Institute, Wellcome Genome Campus, Cambridge, UK., Memon D; European Molecular Biology Laboratory (EMBL), European Bioinformatics Institute, Wellcome Genome Campus, Cambridge, UK., Hernandez-Armenta C; European Molecular Biology Laboratory (EMBL), European Bioinformatics Institute, Wellcome Genome Campus, Cambridge, UK., Lyu J; QBI COVID-19 Research Group (QCRG), San Francisco, CA, USA.; Quantitative Biosciences Institute (QBI), University of California San Francisco, San Francisco, CA, USA.; Department of Pharmaceutical Chemistry, University of California San Francisco, San Francisco, CA, USA., Mathy CJP; QBI COVID-19 Research Group (QCRG), San Francisco, CA, USA.; Quantitative Biosciences Institute (QBI), University of California San Francisco, San Francisco, CA, USA.; Department of Bioengineering and Therapeutic Sciences, University of California San Francisco, San Francisco, CA, USA.; The UC Berkeley-UCSF Graduate Program in Bioengineering, University of California San Francisco, San Francisco, CA, USA., Perica T; QBI COVID-19 Research Group (QCRG), San Francisco, CA, USA.; Quantitative Biosciences Institute (QBI), University of California San Francisco, San Francisco, CA, USA.; Department of Bioengineering and Therapeutic Sciences, University of California San Francisco, San Francisco, CA, USA., Pilla KB; QBI COVID-19 Research Group (QCRG), San Francisco, CA, USA.; Quantitative Biosciences Institute (QBI), University of California San Francisco, San Francisco, CA, USA.; Department of Bioengineering and Therapeutic Sciences, University of California San Francisco, San Francisco, CA, USA., Ganesan SJ; QBI COVID-19 Research Group (QCRG), San Francisco, CA, USA.; Quantitative Biosciences Institute (QBI), University of California San Francisco, San Francisco, CA, USA.; Department of Bioengineering and Therapeutic Sciences, University of California San Francisco, San Francisco, CA, USA., Saltzberg DJ; QBI COVID-19 Research Group (QCRG), San Francisco, CA, USA.; Quantitative Biosciences Institute (QBI), University of California San Francisco, San Francisco, CA, USA.; Department of Bioengineering and Therapeutic Sciences, University of California San Francisco, San Francisco, CA, USA., Rakesh R; QBI COVID-19 Research Group (QCRG), San Francisco, CA, USA.; Quantitative Biosciences Institute (QBI), University of California San Francisco, San Francisco, CA, USA.; Department of Bioengineering and Therapeutic Sciences, University of California San Francisco, San Francisco, CA, USA., Liu X; QBI COVID-19 Research Group (QCRG), San Francisco, CA, USA.; Quantitative Biosciences Institute (QBI), University of California San Francisco, San Francisco, CA, USA.; Department of Pharmaceutical Chemistry, University of California San Francisco, San Francisco, CA, USA., Rosenthal SB; Center for Computational Biology and Bioinformatics, Department of Medicine, University of California San Diego, San Diego, CA, USA., Calviello L; QBI COVID-19 Research Group (QCRG), San Francisco, CA, USA.; Department of Cell and Tissue Biology, University of California San Francisco, San Francisco, CA, USA., Venkataramanan S; QBI COVID-19 Research Group (QCRG), San Francisco, CA, USA.; Department of Cell and Tissue Biology, University of California San Francisco, San Francisco, CA, USA., Liboy-Lugo J; QBI COVID-19 Research Group (QCRG), San Francisco, CA, USA.; Department of Cell and Tissue Biology, University of California San Francisco, San Francisco, CA, USA., Lin Y; QBI COVID-19 Research Group (QCRG), San Francisco, CA, USA.; Department of Cell and Tissue Biology, University of California San Francisco, San Francisco, CA, USA., Huang XP; Department of Pharmacology, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, NC, USA., Liu Y; Department of Pharmacology, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, NC, USA., Wankowicz SA; QBI COVID-19 Research Group (QCRG), San Francisco, CA, USA.; Quantitative Biosciences Institute (QBI), University of California San Francisco, San Francisco, CA, USA.; Department of Bioengineering and Therapeutic Sciences, University of California San Francisco, San Francisco, CA, USA.; Biophysics Graduate Program, University of California San Francisco, San Francisco, CA, USA., Bohn M; QBI COVID-19 Research Group (QCRG), San Francisco, CA, USA.; Quantitative Biosciences Institute (QBI), University of California San Francisco, San Francisco, CA, USA.; Department of Pharmaceutical Chemistry, University of California San Francisco, San Francisco, CA, USA., Safari M; QBI COVID-19 Research Group (QCRG), San Francisco, CA, USA.; Quantitative Biosciences Institute (QBI), University of California San Francisco, San Francisco, CA, USA.; Department of Biochemistry and Biophysics, University of California San Francisco, San Francisco, CA, USA., Ugur FS; QBI COVID-19 Research Group (QCRG), San Francisco, CA, USA.; Quantitative Biosciences Institute (QBI), University of California San Francisco, San Francisco, CA, USA.; Department of Cellular and Molecular Pharmacology, University of California San Francisco, San Francisco, CA, USA.; Department of Pharmaceutical Chemistry, University of California San Francisco, San Francisco, CA, USA., Koh C; Viral Populations and Pathogenesis Unit, CNRS UMR 3569, Institut Pasteur, Paris, France., Savar NS; Viral Populations and Pathogenesis Unit, CNRS UMR 3569, Institut Pasteur, Paris, France., Tran QD; Viral Populations and Pathogenesis Unit, CNRS UMR 3569, Institut Pasteur, Paris, France., Shengjuler D; Viral Populations and Pathogenesis Unit, CNRS UMR 3569, Institut Pasteur, Paris, France., Fletcher SJ; Viral Populations and Pathogenesis Unit, CNRS UMR 3569, Institut Pasteur, Paris, France., O'Neal MC; Zoic Labs, Culver City, CA, USA., Cai Y; Zoic Labs, Culver City, CA, USA., Chang JCJ; Zoic Labs, Culver City, CA, USA., Broadhurst DJ; Zoic Labs, Culver City, CA, USA., Klippsten S; Zoic Labs, Culver City, CA, USA., Sharp PP; Department of Cellular and Molecular Pharmacology, University of California San Francisco, San Francisco, CA, USA., Wenzell NA; QBI COVID-19 Research Group (QCRG), San Francisco, CA, USA.; Quantitative Biosciences Institute (QBI), University of California San Francisco, San Francisco, CA, USA.; Department of Cellular and Molecular Pharmacology, University of California San Francisco, San Francisco, CA, USA., Kuzuoglu-Ozturk D; QBI COVID-19 Research Group (QCRG), San Francisco, CA, USA.; Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, USA.; Department of Urology, University of California San Francisco, San Francisco, CA, USA., Wang HY; QBI COVID-19 Research Group (QCRG), San Francisco, CA, USA.; Quantitative Biosciences Institute (QBI), University of California San Francisco, San Francisco, CA, USA.; Department of Cellular and Molecular Pharmacology, University of California San Francisco, San Francisco, CA, USA., Trenker R; QBI COVID-19 Research Group (QCRG), San Francisco, CA, USA.; Quantitative Biosciences Institute (QBI), University of California San Francisco, San Francisco, CA, USA.; Cardiovascular Research Institute, University of California San Francisco, San Francisco, CA, USA., Young JM; Division of Basic Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA, USA., Cavero DA; QBI COVID-19 Research Group (QCRG), San Francisco, CA, USA.; J. David Gladstone Institutes, San Francisco, CA, USA.; George William Hooper Foundation, Department of Microbiology and Immunology, University of California San Francisco, San Francisco, CA, USA., Hiatt J; QBI COVID-19 Research Group (QCRG), San Francisco, CA, USA.; J. David Gladstone Institutes, San Francisco, CA, USA.; Medical Scientist Training Program, University of California San Francisco, San Francisco, CA, USA., Roth TL; QBI COVID-19 Research Group (QCRG), San Francisco, CA, USA.; J. David Gladstone Institutes, San Francisco, CA, USA.; George William Hooper Foundation, Department of Microbiology and Immunology, University of California San Francisco, San Francisco, CA, USA.; Medical Scientist Training Program, University of California San Francisco, San Francisco, CA, USA., Rathore U; QBI COVID-19 Research Group (QCRG), San Francisco, CA, USA.; J. David Gladstone Institutes, San Francisco, CA, USA.; George William Hooper Foundation, Department of Microbiology and Immunology, University of California San Francisco, San Francisco, CA, USA., Subramanian A; QBI COVID-19 Research Group (QCRG), San Francisco, CA, USA.; Quantitative Biosciences Institute (QBI), University of California San Francisco, San Francisco, CA, USA.; George William Hooper Foundation, Department of Microbiology and Immunology, University of California San Francisco, San Francisco, CA, USA., Noack J; QBI COVID-19 Research Group (QCRG), San Francisco, CA, USA.; Quantitative Biosciences Institute (QBI), University of California San Francisco, San Francisco, CA, USA.; George William Hooper Foundation, Department of Microbiology and Immunology, University of California San Francisco, San Francisco, CA, USA., Hubert M; Virus and Immunity Unit, Institut Pasteur, Paris, France., Stroud RM; QBI COVID-19 Research Group (QCRG), San Francisco, CA, USA.; Quantitative Biosciences Institute (QBI), University of California San Francisco, San Francisco, CA, USA.; Department of Biochemistry and Biophysics, University of California San Francisco, San Francisco, CA, USA., Frankel AD; QBI COVID-19 Research Group (QCRG), San Francisco, CA, USA.; Quantitative Biosciences Institute (QBI), University of California San Francisco, San Francisco, CA, USA.; Department of Biochemistry and Biophysics, University of California San Francisco, San Francisco, CA, USA., Rosenberg OS; QBI COVID-19 Research Group (QCRG), San Francisco, CA, USA.; Quantitative Biosciences Institute (QBI), University of California San Francisco, San Francisco, CA, USA.; Department of Biochemistry and Biophysics, University of California San Francisco, San Francisco, CA, USA.; Department of Medicine, University of California San Francisco, San Francisco, CA, USA., Verba KA; QBI COVID-19 Research Group (QCRG), San Francisco, CA, USA.; Quantitative Biosciences Institute (QBI), University of California San Francisco, San Francisco, CA, USA.; Department of Pharmaceutical Chemistry, University of California San Francisco, San Francisco, CA, USA., Agard DA; QBI COVID-19 Research Group (QCRG), San Francisco, CA, USA.; Quantitative Biosciences Institute (QBI), University of California San Francisco, San Francisco, CA, USA.; Department of Biochemistry and Biophysics, University of California San Francisco, San Francisco, CA, USA., Ott M; QBI COVID-19 Research Group (QCRG), San Francisco, CA, USA.; Quantitative Biosciences Institute (QBI), University of California San Francisco, San Francisco, CA, USA.; J. David Gladstone Institutes, San Francisco, CA, USA.; Department of Medicine, University of California San Francisco, San Francisco, CA, USA., Emerman M; Division of Human Biology, Fred Hutchinson Cancer Research Center, Seattle, WA, USA., Jura N; QBI COVID-19 Research Group (QCRG), San Francisco, CA, USA.; Quantitative Biosciences Institute (QBI), University of California San Francisco, San Francisco, CA, USA.; Department of Cellular and Molecular Pharmacology, University of California San Francisco, San Francisco, CA, USA.; Cardiovascular Research Institute, University of California San Francisco, San Francisco, CA, USA., von Zastrow M; QBI COVID-19 Research Group (QCRG), San Francisco, CA, USA.; Quantitative Biosciences Institute (QBI), University of California San Francisco, San Francisco, CA, USA.; Department of Cellular and Molecular Pharmacology, University of California San Francisco, San Francisco, CA, USA.; Department of Psychiatry, University of California San Francisco, San Francisco, CA, USA., Verdin E; QBI COVID-19 Research Group (QCRG), San Francisco, CA, USA.; Department of Medicine, University of California San Francisco, San Francisco, CA, USA.; Buck Institute for Research on Aging, Novato, CA, USA., Ashworth A; QBI COVID-19 Research Group (QCRG), San Francisco, CA, USA.; Quantitative Biosciences Institute (QBI), University of California San Francisco, San Francisco, CA, USA.; Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, USA., Schwartz O; Virus and Immunity Unit, Institut Pasteur, Paris, France., d'Enfert C; Direction Scientifique, Institut Pasteur, Paris, France., Mukherjee S; QBI COVID-19 Research Group (QCRG), San Francisco, CA, USA.; Quantitative Biosciences Institute (QBI), University of California San Francisco, San Francisco, CA, USA.; George William Hooper Foundation, Department of Microbiology and Immunology, University of California San Francisco, San Francisco, CA, USA., Jacobson M; QBI COVID-19 Research Group (QCRG), San Francisco, CA, USA.; Quantitative Biosciences Institute (QBI), University of California San Francisco, San Francisco, CA, USA.; Department of Pharmaceutical Chemistry, University of California San Francisco, San Francisco, CA, USA., Malik HS; Division of Basic Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA, USA., Fujimori DG; QBI COVID-19 Research Group (QCRG), San Francisco, CA, USA.; Quantitative Biosciences Institute (QBI), University of California San Francisco, San Francisco, CA, USA.; Department of Cellular and Molecular Pharmacology, University of California San Francisco, San Francisco, CA, USA.; Department of Pharmaceutical Chemistry, University of California San Francisco, San Francisco, CA, USA., Ideker T; QBI COVID-19 Research Group (QCRG), San Francisco, CA, USA.; Division of Genetics, Department of Medicine, University of California San Diego, San Diego, CA, USA., Craik CS; QBI COVID-19 Research Group (QCRG), San Francisco, CA, USA.; Quantitative Biosciences Institute (QBI), University of California San Francisco, San Francisco, CA, USA.; Department of Pharmaceutical Chemistry, University of California San Francisco, San Francisco, CA, USA.; Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, USA., Floor SN; QBI COVID-19 Research Group (QCRG), San Francisco, CA, USA.; Department of Cell and Tissue Biology, University of California San Francisco, San Francisco, CA, USA.; Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, USA., Fraser JS; QBI COVID-19 Research Group (QCRG), San Francisco, CA, USA.; Quantitative Biosciences Institute (QBI), University of California San Francisco, San Francisco, CA, USA.; Department of Bioengineering and Therapeutic Sciences, University of California San Francisco, San Francisco, CA, USA., Gross JD; QBI COVID-19 Research Group (QCRG), San Francisco, CA, USA.; Quantitative Biosciences Institute (QBI), University of California San Francisco, San Francisco, CA, USA.; Department of Pharmaceutical Chemistry, University of California San Francisco, San Francisco, CA, USA., Sali A; QBI COVID-19 Research Group (QCRG), San Francisco, CA, USA.; Quantitative Biosciences Institute (QBI), University of California San Francisco, San Francisco, CA, USA.; Department of Pharmaceutical Chemistry, University of California San Francisco, San Francisco, CA, USA.; Department of Bioengineering and Therapeutic Sciences, University of California San Francisco, San Francisco, CA, USA., Roth BL; Department of Pharmacology, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, NC, USA., Ruggero D; QBI COVID-19 Research Group (QCRG), San Francisco, CA, USA.; Quantitative Biosciences Institute (QBI), University of California San Francisco, San Francisco, CA, USA.; Department of Cellular and Molecular Pharmacology, University of California San Francisco, San Francisco, CA, USA.; Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, USA.; Department of Urology, University of California San Francisco, San Francisco, CA, USA., Taunton J; QBI COVID-19 Research Group (QCRG), San Francisco, CA, USA.; Quantitative Biosciences Institute (QBI), University of California San Francisco, San Francisco, CA, USA.; Department of Cellular and Molecular Pharmacology, University of California San Francisco, San Francisco, CA, USA., Kortemme T; QBI COVID-19 Research Group (QCRG), San Francisco, CA, USA.; Quantitative Biosciences Institute (QBI), University of California San Francisco, San Francisco, CA, USA.; Department of Bioengineering and Therapeutic Sciences, University of California San Francisco, San Francisco, CA, USA.; The UC Berkeley-UCSF Graduate Program in Bioengineering, University of California San Francisco, San Francisco, CA, USA., Beltrao P; QBI COVID-19 Research Group (QCRG), San Francisco, CA, USA.; European Molecular Biology Laboratory (EMBL), European Bioinformatics Institute, Wellcome Genome Campus, Cambridge, UK., Vignuzzi M; Viral Populations and Pathogenesis Unit, CNRS UMR 3569, Institut Pasteur, Paris, France. marco.vignuzzi@pasteur.fr., García-Sastre A; Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA. Adolfo.Garcia-Sastre@mssm.edu.; Global Health and Emerging Pathogens Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA. Adolfo.Garcia-Sastre@mssm.edu.; Department of Medicine, Division of Infectious Diseases, Icahn School of Medicine at Mount Sinai, New York, NY, USA. Adolfo.Garcia-Sastre@mssm.edu.; The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA. Adolfo.Garcia-Sastre@mssm.edu., Shokat KM; QBI COVID-19 Research Group (QCRG), San Francisco, CA, USA. Kevan.Shokat@ucsf.edu.; Quantitative Biosciences Institute (QBI), University of California San Francisco, San Francisco, CA, USA. Kevan.Shokat@ucsf.edu.; Department of Cellular and Molecular Pharmacology, University of California San Francisco, San Francisco, CA, USA. Kevan.Shokat@ucsf.edu.; Howard Hughes Medical Institute, University of California San Francisco, San Francisco, CA, USA. Kevan.Shokat@ucsf.edu., Shoichet BK; QBI COVID-19 Research Group (QCRG), San Francisco, CA, USA. shoichet@cgl.ucsf.edu.; Quantitative Biosciences Institute (QBI), University of California San Francisco, San Francisco, CA, USA. shoichet@cgl.ucsf.edu.; Department of Pharmaceutical Chemistry, University of California San Francisco, San Francisco, CA, USA. shoichet@cgl.ucsf.edu., Krogan NJ; QBI COVID-19 Research Group (QCRG), San Francisco, CA, USA. nevan.krogan@ucsf.edu.; Quantitative Biosciences Institute (QBI), University of California San Francisco, San Francisco, CA, USA. nevan.krogan@ucsf.edu.; J. David Gladstone Institutes, San Francisco, CA, USA. nevan.krogan@ucsf.edu.; Department of Cellular and Molecular Pharmacology, University of California San Francisco, San Francisco, CA, USA. nevan.krogan@ucsf.edu.; Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA. nevan.krogan@ucsf.edu.
المصدر: Nature [Nature] 2020 Jul; Vol. 583 (7816), pp. 459-468. Date of Electronic Publication: 2020 Apr 30.
نوع المنشور: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
اللغة: English
بيانات الدورية: Publisher: Nature Publishing Group Country of Publication: England NLM ID: 0410462 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1476-4687 (Electronic) Linking ISSN: 00280836 NLM ISO Abbreviation: Nature Subsets: MEDLINE
أسماء مطبوعة: Publication: Basingstoke : Nature Publishing Group
Original Publication: London, Macmillan Journals ltd.
مواضيع طبية MeSH: Drug Repositioning* , Molecular Targeted Therapy* , Protein Interaction Maps*, Betacoronavirus/*drug effects , Coronavirus Infections/*drug therapy , Coronavirus Infections/*metabolism , Pneumonia, Viral/*drug therapy , Pneumonia, Viral/*metabolism , Viral Proteins/*metabolism, Animals ; Antiviral Agents/classification ; Antiviral Agents/pharmacology ; Betacoronavirus/genetics ; Betacoronavirus/metabolism ; Betacoronavirus/pathogenicity ; COVID-19 ; Chlorocebus aethiops ; Cloning, Molecular ; Coronavirus Infections/immunology ; Coronavirus Infections/virology ; Drug Evaluation, Preclinical ; HEK293 Cells ; Host-Pathogen Interactions/drug effects ; Humans ; Immunity, Innate ; Mass Spectrometry ; Pandemics ; Pneumonia, Viral/immunology ; Pneumonia, Viral/virology ; Protein Binding ; Protein Biosynthesis/drug effects ; Protein Domains ; Protein Interaction Mapping ; Receptors, sigma/metabolism ; SARS-CoV-2 ; SKP Cullin F-Box Protein Ligases/metabolism ; Vero Cells ; Viral Proteins/genetics ; COVID-19 Drug Treatment
مستخلص: A newly described coronavirus named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which is the causative agent of coronavirus disease 2019 (COVID-19), has infected over 2.3 million people, led to the death of more than 160,000 individuals and caused worldwide social and economic disruption 1,2 . There are no antiviral drugs with proven clinical efficacy for the treatment of COVID-19, nor are there any vaccines that prevent infection with SARS-CoV-2, and efforts to develop drugs and vaccines are hampered by the limited knowledge of the molecular details of how SARS-CoV-2 infects cells. Here we cloned, tagged and expressed 26 of the 29 SARS-CoV-2 proteins in human cells and identified the human proteins that physically associated with each of the SARS-CoV-2 proteins using affinity-purification mass spectrometry, identifying 332 high-confidence protein-protein interactions between SARS-CoV-2 and human proteins. Among these, we identify 66 druggable human proteins or host factors targeted by 69 compounds (of which, 29 drugs are approved by the US Food and Drug Administration, 12 are in clinical trials and 28 are preclinical compounds). We screened a subset of these in multiple viral assays and found two sets of pharmacological agents that displayed antiviral activity: inhibitors of mRNA translation and predicted regulators of the sigma-1 and sigma-2 receptors. Further studies of these host-factor-targeting agents, including their combination with drugs that directly target viral enzymes, could lead to a therapeutic regimen to treat COVID-19.
التعليقات: Comment in: Nat Rev Immunol. 2020 Jun;20(6):351. (PMID: 32303698)
Update of: bioRxiv. 2020 Mar 22;:. (PMID: 32511329)
Comment in: Psychiatry Res. 2021 Jan;295:113626. (PMID: 33290940)
Comment in: Schizophr Res. 2022 Mar;241:140-141. (PMID: 35123336)
References: Nucleic Acids Res. 2017 Jan 4;45(D1):D1100-D1106. (PMID: 27924013)
Nat Struct Mol Biol. 2018 Oct;25(10):981-987. (PMID: 30291362)
Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954. (PMID: 27899562)
Mol Cell Biol. 2017 Oct 13;37(21):. (PMID: 28784718)
Biochem Biophys Res Commun. 2011 Nov 25;415(3):519-25. (PMID: 22079628)
Mol Cell. 2005 Jan 7;17(1):93-102. (PMID: 15629720)
Nucleic Acids Res. 2019 Jan 8;47(D1):D559-D563. (PMID: 30357367)
Cell. 2018 Dec 13;175(7):1931-1945.e18. (PMID: 30550790)
Lancet. 2020 Feb 15;395(10223):470-473. (PMID: 31986257)
Nat Microbiol. 2019 Jun;4(6):985-995. (PMID: 30833725)
Emerg Microbes Infect. 2020 Dec;9(1):221-236. (PMID: 31987001)
Nat Biotechnol. 2014 Mar;32(3):223-6. (PMID: 24727771)
J Exp Clin Cancer Res. 2019 Dec 5;38(1):483. (PMID: 31805977)
Nature. 2011 Dec 21;481(7381):365-70. (PMID: 22190034)
N Engl J Med. 2020 Feb 20;382(8):727-733. (PMID: 31978945)
Biomolecules. 2014 Oct 13;4(4):897-930. (PMID: 25314029)
Mol Syst Biol. 2011 Oct 11;7:539. (PMID: 21988835)
Bioinformatics. 2010 Mar 1;26(5):689-91. (PMID: 20061306)
Mol Syst Biol. 2019 Feb 18;15(2):e8503. (PMID: 30777892)
Nature. 2012 Mar 14;483(7390):428-33. (PMID: 22419161)
Sci Rep. 2016 Jun 16;6:28249. (PMID: 27306108)
J Chem Inf Model. 2010 Sep 27;50(9):1561-73. (PMID: 20735049)
Biochem Biophys Res Commun. 2012 Jun 8;422(3):501-7. (PMID: 22588174)
Cell Microbiol. 2007 Sep;9(9):2218-29. (PMID: 17490409)
PLoS Biol. 2008 Sep 16;6(9):e226. (PMID: 18798692)
Lancet Infect Dis. 2007 Aug;7(8):549-58. (PMID: 17646028)
Elife. 2015 Dec 10;4:. (PMID: 26651998)
Mol Cell Biol. 2017 Feb 1;37(4):. (PMID: 27920254)
Immunity. 2016 Jan 19;44(1):46-58. (PMID: 26789921)
J Proteomics. 2014 Apr 04;100:37-43. (PMID: 24513533)
Annu Rev Physiol. 2009;71:451-64. (PMID: 18817512)
Proc Natl Acad Sci U S A. 2014 Jun 24;111(25):9127-32. (PMID: 24927547)
Cell. 2015 Jul 16;162(2):425-440. (PMID: 26186194)
Virus Res. 2015 Aug 3;206:120-33. (PMID: 25736566)
Nat Biotechnol. 2008 Dec;26(12):1367-72. (PMID: 19029910)
Mol Cell. 2018 Aug 16;71(4):637-648.e5. (PMID: 30118682)
Cold Spring Harb Perspect Biol. 2019 May 1;11(5):. (PMID: 30082464)
J Virol. 2018 Sep 26;92(20):. (PMID: 30068649)
Nature. 2009 Apr 9;458(7239):732-6. (PMID: 19360080)
N Engl J Med. 2020 Apr 30;382(18):1677-1679. (PMID: 32109012)
Protein Eng Des Sel. 2008 Nov;21(11):639-44. (PMID: 18753194)
Sci Transl Med. 2020 Apr 29;12(541):. (PMID: 32253226)
Assay Drug Dev Technol. 2010 Dec;8(6):727-42. (PMID: 21158687)
IUCrJ. 2014 May 30;1(Pt 4):213-20. (PMID: 25075342)
Adv Virus Res. 2016;96:165-192. (PMID: 27712623)
J Virol. 2011 Jul;85(13):6381-9. (PMID: 21507972)
Immunity. 2011 Sep 23;35(3):426-40. (PMID: 21903422)
Genome Res. 2003 Nov;13(11):2498-504. (PMID: 14597658)
Science. 2019 Jul 5;365(6448):. (PMID: 31273098)
Nat Biotechnol. 2019 Apr;37(4):420-423. (PMID: 30778233)
Nature. 2020 Feb;578(7794):306-310. (PMID: 31969702)
Int J Mol Sci. 2011;12(6):4027-52. (PMID: 21747723)
J Gen Virol. 2003 Sep;84(Pt 9):2305-2315. (PMID: 12917450)
Nucleic Acids Res. 2015 Jul 1;43(W1):W389-94. (PMID: 25883141)
Proc Natl Acad Sci U S A. 2003 Nov 11;100(23):13190-5. (PMID: 14585926)
Emerg Infect Dis. 2020 Jun;26(6):1266-1273. (PMID: 32160149)
Nature. 2012 Dec 13;492(7428):215-20. (PMID: 23235874)
Trends Microbiol. 2016 Jun;24(6):490-502. (PMID: 27012512)
Nat Commun. 2020 Jan 10;11(1):222. (PMID: 31924756)
J Mol Biol. 2001 Jan 19;305(3):567-80. (PMID: 11152613)
Ann Hematol. 2019 Sep;98(9):2139-2150. (PMID: 31240472)
Curr Protoc Bioinformatics. 2015 Mar 09;49:8.19.1-8.19.16. (PMID: 25754993)
Mol Cell Proteomics. 2014 Sep;13(9):2513-26. (PMID: 24942700)
PLoS One. 2018 Jan 11;13(1):e0189209. (PMID: 29324744)
Nat Rev Genet. 2020 Jun;21(6):339-354. (PMID: 32060427)
J Chem Inf Model. 2015 Nov 23;55(11):2324-37. (PMID: 26479676)
Cell. 2020 Apr 16;181(2):271-280.e8. (PMID: 32142651)
Antimicrob Agents Chemother. 2015 Feb;59(2):1088-99. (PMID: 25487801)
Methods Mol Biol. 2015;1282:1-23. (PMID: 25720466)
Cell. 2012 Mar 30;149(1):214-31. (PMID: 22464331)
Nature. 2020 Jul;583(7816):469-472. (PMID: 32408336)
Antiviral Res. 2018 Feb;150:123-129. (PMID: 29258862)
Nucleic Acids Res. 2020 Jan 8;48(D1):D1006-D1021. (PMID: 31691834)
Clin Chem. 2020 Apr 1;66(4):549-555. (PMID: 32031583)
Viruses. 2017 Dec 18;9(12):. (PMID: 29258238)
J Virol. 2007 Sep;81(18):9812-24. (PMID: 17596301)
Nature. 2020 Mar;579(7798):265-269. (PMID: 32015508)
معلومات مُعتمدة: F32 GM133144 United States GM NIGMS NIH HHS; R01 GM024485 United States GM NIGMS NIH HHS; 1R01CA244550 United States NH NIH HHS; T32 AI060537 United States AI NIAID NIH HHS; R01 GM117189 United States GM NIGMS NIH HHS; R01 AI122747 United States AI NIAID NIH HHS; F32 CA239333 United States CA NCI NIH HHS; R01 CA221969 United States CA NCI NIH HHS; K08 HL124068 United States HL NHLBI NIH HHS; 1F32CA236347-01 United States NH NIH HHS; R35 GM122481 United States GM NIGMS NIH HHS; P01 AI063302 United States AI NIAID NIH HHS; F30 CA239476 United States CA NCI NIH HHS; P50 AI150476 United States AI NIAID NIH HHS; R01 AI143292 United States AI NIAID NIH HHS; F32 CA236347 United States CA NCI NIH HHS; R01 GM140440 United States GM NIGMS NIH HHS; HHSN272201400008C United States AI NIAID NIH HHS; R01 AI120694 United States AI NIAID NIH HHS; T32 GM008284 United States GM NIGMS NIH HHS; T32 GM067547 United States GM NIGMS NIH HHS; United States HHMI Howard Hughes Medical Institute; U19 AI135990 United States AI NIAID NIH HHS; R01 CA244550 United States CA NCI NIH HHS; R01 AI118974 United States AI NIAID NIH HHS; P30 CA023100 United States CA NCI NIH HHS; R35 GM118099 United States GM NIGMS NIH HHS; R01 HG009979 United States HG NHGRI NIH HHS; P01 AI120943 United States AI NIAID NIH HHS; P30 AI027763 United States AI NIAID NIH HHS; U19 AI135972 United States AI NIAID NIH HHS; T32 GM064337 United States GM NIGMS NIH HHS
المشرفين على المادة: 0 (Antiviral Agents)
0 (Receptors, sigma)
0 (Viral Proteins)
EC 2.3.2.27 (SKP Cullin F-Box Protein Ligases)
تواريخ الأحداث: Date Created: 20200501 Date Completed: 20200721 Latest Revision: 20231221
رمز التحديث: 20231221
مُعرف محوري في PubMed: PMC7431030
DOI: 10.1038/s41586-020-2286-9
PMID: 32353859
قاعدة البيانات: MEDLINE
الوصف
تدمد:1476-4687
DOI:10.1038/s41586-020-2286-9